Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from NeuroFrontiers
Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial
Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease
Advancing MOGAD Care
Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
Get summaries like this every morning.
Free AI-powered recaps of NeuroFrontiers and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.